Zydus focuses in US on complex pipeline

Zydus Cadila is focusing on generics that are difficult to develop and manufacture, as well as on specialty brands, in the US as the Indian company aims to improve its profit margins. The group is also seeking inorganic growth through “selective mergers and acquisitions” in the US, India, and its Emerging Markets region in Asia and Africa.

Zydus Cadila is focusing on generics that are difficult to develop and manufacture, as well as on specialty brands, in the US as the Indian company aims to improve its profit margins. The group is also seeking inorganic growth through “selective mergers and acquisitions” in the US, India, and its Emerging Markets region in Asia and Africa.

Citing Iqvia data for the 12 months ended January 2018, the Indian company said it ranked ninth among US generics...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin